In the News
Alzheon Gets $10M to Take Castoff Alzheimer’s Drug Into Pivotal Test
Run by a veteran of drug R&D for Alzheimer’s disease, Alzheon is betting that a smart trial design and a little chemistry work could [...]
Alzheimer’s startup Alzheon bags $10M and beats a path to Phase III
The veteran Alzheimer's researchers at Alzheon believe their novel treatment for the disease has a chance to come through where so many others have failed. Alzheon's [...]
Lexington’s Alzheon gives its own Alzheimer’s news to rival Biogen’s
While it’s the biggest, Biogen is not the only Bay State biotech presenting promising data for an Alzheimer’s drug this morning. The small Lexington-based biotech, Alzheon, [...]
Six drugs that could change the world
The strength of the state’s world-class drug developers is usually measured in terms of jobs and economics, rather than the effect on human health in coming [...]
Startup Finds Hope in Second Look at “Failed” Alzheimer’s Drugs
Alzheon will first take a closer look at a drug designed to target the brain-damaging amyloid plaques that are the hallmarks of Alzheimer’s. In the hands [...]
Alzheimer’s team tackles a daunting R&D field with a new game plan
The drug is tramiprosate, which flunked a big study back in 2009. It's been rebuilt, so to speak, so it can be delivered through the gut [...]
Alzheon Emerges From Stealth, Hunts for Alzheimer’s Castoffs
Clinical trial flops have become the norm for Alzheimer’s disease treatments, despite the billions put into research for the memory-robbing disorder. But a new Lexington, MA-based [...]
Press Releases
Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801
Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker ResultsSelectivity for Amyloid [...]
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
FRAMINGHAM, Mass., January 7, 2020 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative [...]
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course Publication Outlines Therapeutic Characteristics [...]
Alzheon Presents Data on the Discovery of 3-SPA, an Endogenous Substance in the Human Brain, at the Alzheimer’s Association International Conference
3-SPA, also a Product of ALZ-801, Prevents Formation of Toxic Beta Amyloid Oligomers, the Key Driver of Alzheimer’s Disease FRAMINGHAM, Mass., July 14, 2019 – Alzheon, Inc., a [...]
Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease
Publication Details Discovery of 3-Sulfopropanoic Acid, the Primary Metabolite of Tramiprosate and its Prodrug ALZ-801, in Cerebrospinal Fluid of Healthy Subjects as well as Alzheimer’s Patients [...]
Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors
Framingham, Mass. – August 6, 2018 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other [...]